New Frost Sullivan research reveals Asia as Preferred Destination for Clinical Trials

Sydney, Aus, Mar 3, 2017 - (ACN Newswire) - Frost & Sullivan today released its latest white paper, 'Asia: Preferred Destination for Clinical Trials', with Asia Pacific specialist CRO Novotech. Research from the new white paper revealed Asia is quickly becoming a clinical research powerhouse; facilitated by the availability of vast treatment-naive patient pools, exceptional clinical infrastructure and talent, and low operational costs.Commenting on the white paper, Novotech CEO Dr. John Moller said "Asia is an increasingly attractive destination for our biotech clients. The huge patient pools available in Asia are mainly concentrated in easily accessible urban areas, meaning that trials tend to recruit faster. In addition, the cost of trials in most Asian countries is significantly lower than the West.""Now is an exciting time for clinical trials taking place in Asia. There are a number of large, state-of-the-art clinical trial centers in Asia that meet patient enrolment and retention goals, generate high-quality data, and are led by globally recognised key opinion leaders. Regulatory processes in Asia are continuing to become more streamlined. Novotech is actively working with a number of regulatory authorities and clinical trial centres to improve approval processes and timelines," said Dr. Moller.Novotech presented the white paper to an audience of senior biotechnology and pharmaceutical executives in a private event at Outsourcing Clinical Trials - West Coast 2017, held in Burlingame, California (USA).

The new Frost & Sullivan White Paper, 'Asia: Preferred Destination for Clinical Trials', is available as Executive Summary (http://bit.ly/2lkrhAB) or Full White Paper (http://bit.ly/2mkqHmn).

About Novotech

Headquartered in Sydney, Novotech is internationally recognised as a leading regional full-service contract research organisation (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region.

Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management.

Novotech's strong Asia Pacific presence includes running clinical trials in all key regional markets. Novotech also has worldwide reach through the company's network of strategic partners. For more information, please visit www.novotech-cro.com.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the Global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies? www.frost.com.

Please contact:Susan Fitzpatrick-NapierDigital Mantra GroupT: +61 2 8218 2144 / +1 650 798 5238 E: susan@dmgpr.comW: www.digitalmantragroup.com

Copyright 2017 ACN Newswire. All rights reserved. www.acnnewswire.com